symbol |
CBMG |
会社名 | Cellular Biomedicine Group Inc (セルラ―・バイオメディシン・グル―プ) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Biotechnology: Biological Products (No Diagnostic Substances)
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms such as Immune Cell therapy for treatment of broad range of cancers using Vaccine T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies Chimeric Antigen Receptor T cell (CAR-T) and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms to treat serious chronic and degenerative diseases such as cancer orthopedic diseases. セルラ―・バイオメディシン・グル―プは米国のバイオ医薬品企業。独自のセル技術を利用し、癌や変性疾患の新たな治療法の開発に従事。癌治療に腫瘍細胞特異的樹状細胞、関節疾患向けヒト脂肪由来間葉系前駆細胞、ヒト臍帯由来間葉系前駆細胞、中枢神経系疾患治療にヒト胚性運動ニュ―ロン前駆細胞およびヒト胚性神経前駆細胞を扱う。
|
本社所在地 | 19925 Stevens Creek Blvd. Suite 100 Cupertino CA 95014 USA |
代表者氏名 | Terry A. Belmont テリー・A・ベルモント |
代表者役職名 | Chairman of the Board 取締役会会長 |
電話番号 | +1 408-973-7884 |
設立年月日 | 37043 |
市場名 | NASDAQ National Market System |
ipoyear | ―年 |
従業員数 | 125人 |
url | www.cellbiomedgroup.com |
nasdaq_url | https://www.nasdaq.com/symbol/cbmg |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -28.33412 |
終値(lastsale) | 17.52 |
時価総額(marketcap) | 322722972.72 |
時価総額 | 時価総額(百万ドル) 255.27820 |
売上高 | 売上高(百万ドル) 0.30375 |
企業価値(EV) | 企業価値(EV)(百万ドル) 220.49233 |
当期純利益 | 当期純利益(百万ドル) -46.80730 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellular Biomedicine Group Inc revenues decreased 20% to $128K. Net loss increased 43% to $17.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other income decrease of 83% to $94K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.87 to -$1.03. |